Iain completed his undergraduate degree in Experimental Psychology at the University of Oxford and gained his PhD in Psychology at the University of Sydney. He is currently an NHMRC Principal Research Fellow, Professor of Psychopharmacology and Director of the Psychopharmacology laboratory.
Iain’s primary interest is in the potential of cannabinoids in treating diseases such as epilepsy, cancer, dementia and pain.
Iain also has broad general research interests in human and preclinical psychopharmacology. He is particularly interested in the neuropeptide oxytocin and the development of small molecules that stimulate the brain oxytocin system to modulate social and addictive behaviours.
An additional interest of Iain’s is in characterising the effects of novel emerging psychoactive substances such as synthetic cannabinoids, mephedrone and MDPV.
PRESENTATION TITLE: Medicinal Cannabis in Australia: Current Status and Future Potential
Access to medicinal cannabis products has been legally possible in Australia for more than two years. However uptake has been relatively slow (around 6000 approvals) and self-medication with illicit products in the community continues to be much more common than legal access. Slow uptake has reflected the complexity of the official access schemes and the expense of available products many of which are imported at great expense. Lack of knowledge around medicinal cannabis amongst the medical profession and optimal prescribing practices has also slowed patient access. Cannabis is a very complex plant with more than 500 bioactive molecules and we are only beginning to understand the therapeutic potential of its components. Research at the Lambert Initiative is aimed at better understanding the efficacy of currently available medicinal cannabis products, while developing novel cannabinoid therapeutics for the future. Cannabinoid science is one of the most exciting and rapidly developing frontiers in contemporary pharmacology.